medicalxpress.com
Cure8 news brief
Why This Matters
If you or someone with MS is treated with rituximab (an anti‑CD20 drug), this study suggests a small increased risk of developing IBD—mostly Crohn’s disease—over time. That risk is rare but may affect treatment decisions and monitoring.
Who Should Pay Attention
Patients with relapsing‑remitting MS on or considering anti‑CD20 therapy, neurologists, gastroenterologists, and researchers interested in immune‑mediated disease overlap.
Study Snapshot
Story typeResearch news
Evidence typeObservational study
Source depthFull source text
What To Know
This population-based observational study suggests an association between anti‑CD20 (rituximab) treatment for MS and increased risk of developing inflammatory bowel disease, primarily Crohn’s disease. The finding is relative risk elevation; absolute risk remained low in the cohorts studied.
Decisions about MS therapy should balance potential rare adverse effects against the established benefits of anti‑CD20 drugs for preventing MS relapses. Clinicians and patients should consider this risk when discussing long-term treatment plans and monitoring.
Keep In Mind
Observational registry data can show associations but cannot prove causation. Absolute risk was low (<2% at 10 years); results are from Swedish registries and compared rituximab with natalizumab, dimethyl fumarate, and fingolimod. Consult the original JAMA Neurology paper and clinicians for clinical decisions.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedicalxpress.com
PublisherMedical Xpress
AuthorsKarolinska Institutet
Indexed viaGoogle News
Source typeWeb article
PublishedOct 22, 2026, 9:03 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Major cardiovascular event risk of advanced therapies in inflammatory bowel diseases: systematic review and meta-analysis
A pooled analysis of cardiovascular risk tied to advanced IBD therapies could affect treatment decisions and monitoring plans because some immune-targeted drugs have been linked to cardiovascular safety concerns in other...
Journal of investigative medicine : the official publication of the American Federation for Clinical Research
EXPRESS: Inflammatory bowel disease and cardiovascular risk: A meta-analysis.
This meta-analysis suggests people with IBD face higher risks of major cardiovascular events (heart attack, ischemic heart disease, ischemic stroke), which may matter for monitoring and preventive care. Higher risk...
IBD Patients at higher risk of Periodontitis, reveals research
This analysis suggests people with IBD (Crohn’s disease and ulcerative colitis) are more likely to have periodontitis. Oral health problems can worsen quality of life and may need separate screening or care.